Montage Gold Corp. (CVE:MAU – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is C$3.27.
Several research firms recently weighed in on MAU. BMO Capital Markets increased their target price on Montage Gold from C$3.00 to C$3.75 in a research report on Friday, October 25th. Cormark increased their target price on Montage Gold from C$2.00 to C$2.50 in a research report on Thursday, August 15th. National Bankshares set a C$2.50 target price on Montage Gold and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. Ventum Cap Mkts upgraded Montage Gold to a “strong-buy” rating in a report on Friday, September 27th. Finally, National Bank Financial upgraded Montage Gold to a “strong-buy” rating in a report on Monday, July 22nd.
Check Out Our Latest Analysis on MAU
Montage Gold Stock Down 2.4 %
Montage Gold (CVE:MAU – Get Free Report) last posted its quarterly earnings data on Thursday, August 22nd. The company reported C($0.03) EPS for the quarter, missing analysts’ consensus estimates of C($0.01) by C($0.02). As a group, equities research analysts anticipate that Montage Gold will post -0.04 EPS for the current fiscal year.
Montage Gold Company Profile
Montage Gold Corp., a precious metals exploration and development company, engages in the exploration and development of mineral properties. Its flagship property is the Koné Gold Project covering an area of 2,259 square kilometers located in the Côte d'Ivoire, West Africa. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Read More
- Five stocks we like better than Montage Gold
- Why Invest in 5G? How to Invest in 5G Stocks
- Intel: Is Now the Time to Be Brave?
- 3 Stocks to Consider Buying in October
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is the Nasdaq? Complete Overview with History
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Montage Gold Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Montage Gold and related companies with MarketBeat.com's FREE daily email newsletter.